The Agency and the Member States shall cooperate to continuously develop pharmacovigilance systems capable of achieving high standards of public health protection for all medicinal products, regardless of the routes of marketing authorisation, including the use of collaborative approaches, to maximise use of resources available within the Union.
Art. 28e Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
In forcesince 2 Jul 2012